Clinical Trial Update: Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy [Phase 2]

View source ↗

Summary

A phase 2 study comparing buparlisib plus paclitaxel versus placebo plus paclitaxel in recurrent or metastatic head and neck squamous cell carcinoma was termina…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Buparlisib (buparlisib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2018-06-26